精神分裂症患者外周血microRNA表达水平在抗精神病药物治疗前后的变化  

Effects of antipsychotics on micro RNA expression of peripheral blood in schizophrenia patients

作　　者：孙欣羊[1] 宋红涛[4] 赵林[5] 仲爱芳 牛威 张理义[1] 卢正斌 戴运华 

机构地区：[1]解放军102医院全军心理疾病防治中心,江苏常州213003 [2]解放军102医院检验科,江苏常州213003 [3]解放军102医院康复科,江苏常州213003 [4]蚌埠医学院精神医学系,安徽蚌埠233030 [5]苏州广济医院精神科,江苏苏州215008 [6]GoPath Laboratories LLC, 1351 Barclay Blvd, Buffalo Grove, IL 60089, USA,233030 [7]GoPath Diagnostic Laboratory Co. Ltd, No.801, Changwuzhonglu, Changzhou, Jiangsu 213164, China

出　　处：《解放军医学杂志》2014年第12期969-974,共6页Medical Journal of Chinese People's Liberation Army

基　　金：南京军区2012年医学科技创新课题(12MA002)~~

摘　　要：目的观察抗精神病药物治疗前后精神分裂症患者外周血部分micro RNA(mi RNA)表达水平的变化。方法选择2012年7月-2013年5月解放军102医院连续收治的61例精神分裂症患者(病例组)和62例正常对照(对照组),采用实时定量荧光PCR检测两组血浆中9种mi RNA(mi R-181b、mi R-195、mi R-132、mi R-212、mi R-30e、mi R-346、mi R-34a、mi R-432、mi R-7)的相对表达水平。选其病例组中阳性与阴性症状量表(PANSS)总分>70分的25例患者,分别在用药前、用药(包括奥氮平、奎硫平、齐拉西酮和利培酮)3周和用药6周时重复检测mi RNA表达水平,并采用PANSS、大体评定量表(GAS)和临床疗效总评量表(CGI)对不同治疗阶段的临床症状及疗效进行评估。结果与对照组比较,病例组血浆mi R-181b、mi R-30e、mi R-346、mi R-34a和mi R-7表达水平显著增高(P<0.05或P<0.01)。与用药前比较,25例患者用药3周后血浆mi R-132表达水平显著降低(P<0.05),用药6周后血浆mi R-132、mi R-181b、mi R-30e和mi R-432表达水平显著降低(P<0.05或P<0.01)。25例患者用药6周后,血浆中9种mi RNA表达水平与对照组比较差异均无统计学意义(P>0.05)。用药过程中,25例患者血浆mi R-132、mi R-195、mi R-30e和mi R-432表达水平与PANSS总分及GAS得分均呈显著相关(P<0.05)。结论 mi R-181b、mi R-132、mi R-30e和mi R-432可能作为预测精神分裂症疾病转归的联合生物标记物。Objective To observe the changes in microRNA （miRNA） expression levels in peripheral blood of schizophrenia patients before and after treatment with antipsychotics. Methods Sixty-one consecutive patients with schizophrenia （case group） and 62 normal controls （control group） hospitalized to the 102nd Hospital of PLA from July 2012 to May 2013 were involved in this study. The relative expression levels of 9 miRNAs （miR-181b, miR-195, miR-132, miR-212, miR-30e, miR-346, miR-34a, miR-432, miR-7） in the peripheral blood plasma of patients in two groups were determined by real-time fluorescence quantitative PCR. Twenty-five schizophrenia patients with total score of Positive and Negative Syndrome Scale （PANSS） 〉70 were selected to determine the miRNA expression levels before and 3 and 6 weeks after antipsychotics （including olanzapine, quetiapine, ziprasidone and risperidone） treatment, and the clinical symptoms and treatment effect in different stages of therapy were assessed by PANSS, Global Assessment Scale （GAS）, and Clinical Global Impression scale （CGI）. Results The expression levels of miR-181b, miR-30e, miR-346, miR-34a and miR-7 in case group were significantly higher than those in control group （P〈0.05, P〈0.01）. In the 25 patients with PANSS 〉70, the expression level of miR-132 lowered 3 weeks after treatment （P〈0.05）, the expression levels of miR-132, miR-181b, miR-30e and miR-432 lowered 6 weeks after treatment （P〈0.05, P〈0.01） compared with those before treatment. After treatment for 6 weeks, all the expression levels of the 9 miRNAs in 25 patients were similar to those in control group （P〉0.05）. The expression of miR-132, miR-195, miR-30e and miR-432 were significantly correlated with the PANSS total score and GAS score along with the treatment course （P〈0.05）. Conclusion The miR-181b, miR-132, miR-30e and miR-432 may be used as biological markers for the prediction of the prognosis of patients with schizophrenia.

关 键 词：精神分裂症 微RNAS 抗精神病药 生物学标记 

分 类 号：R749.3[医药卫生—神经病学与精神病学]